Editas Medicine
EDIT
256 hedge funds and large institutions have $862M invested in Editas Medicine in 2022 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 82 increasing their positions, 67 reducing their positions, and 75 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 67
8.24% less ownership
Funds ownership: 74.48% → 66.23% (-8.2%)
16% less funds holding
Funds holding: 305 → 256 (-49)
20% less call options, than puts
Call options by funds: $31.2M | Put options by funds: $38.8M
36% less capital invested
Capital invested by funds: $1.35B → $862M (-$491M)
59% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 75
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$41M |
| 2 |
BlackRock
New York
|
+$15.6M |
| 3 |
Renaissance Technologies
New York
|
+$12.6M |
| 4 |
CU
CQS (US)
New York
|
+$6.26M |
| 5 |
D.E. Shaw & Co
New York
|
+$5.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$63.6M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
-$30.5M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$30.5M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$29.6M |
| 5 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$14.7M |
EDIT Hedge Fund Activity: Q1 2022 in Review
256 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q1 2022, worth a combined $862M — down 36% from $1.35B a quarter earlier.
Sellers outnumbered buyers: 75 funds closed out of EDIT and 31 opened new positions — a net loss of 44 holders — while 67 trimmed existing stakes and 82 added.
The largest buyer was State Street, adding an estimated $41M. The largest seller was ARK Investment Management, cutting an estimated $63.6M.
- 256 institutional investors held Editas Medicine (EDIT) as of Q1 2022, down from 305 in Q4 2021.
- Funds reported $862M of Editas Medicine stock for Q1 2022, down 36% quarter-over-quarter.
- 31 funds opened new Editas Medicine positions in Q1 2022 and 75 closed out, a net change of -44 holders.
- The largest Editas Medicine buyer in Q1 2022 was State Street, an estimated $41M added.
- The largest Editas Medicine seller in Q1 2022 was ARK Investment Management, an estimated $63.6M sold.
Based on aggregated 13F filings for Q1 2022.